This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chambers, C. Articles by Vu, T. T. Search for Related Content PubMed Articles by Chambers, C. Articles by Vu, T. T. Social Bookmarking                         What's this?

Clinical effectiveness of trastuzumab: early experience

Alberta Cancer Board, Edmonton, Alberta, Canada

Dawn Michelle Dimaculangan, BSc

University of Alberta, Edmonton, Alberta, Canada

KA Grindrod

University of Alberta, Edmonton, Alberta, Canada

John Hanson, MSc

Division of Epidemiology, Cross Cancer Institute, Edmonton, Alberta, Canada

Fruzsina Pataky, BSc(Pharm)

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Thanh Thi Vu, BSc(Pharm)

Cross Cancer Institute, Edmonton, Alberta, Canada

Objective. To assess the clinical effectiveness of trastuzumab among metastatic breast cancer (MBC) patients and compare the results to those reported in the two pivotal clinical trials and product monograph.

Design. Retrospective chart review of all patients who had initiated trastuzumab monotherapy or combination therapy for MBC within the Alberta Cancer Board (ACB) from August 1998 to May 2001.

Setting. Two public tertiary cancer centres in the Canadian province of Alberta.

Patients. Of 90 patients reviewed within the ACB, 72 women were eligible for the study.

Main outcome measures. The primary endpoints measured were time to treatment failure (TTF) and survival. Secondary end-points measured included adverse events and compliance with ACB guidelines for trastuzumab administration.

Results. Among all 72 patients, median TTF was 7.6 months and median survival was 14.4 months. Trastuzumab combination therapy was associated with a significantly longer median TTF compared to trastuzumab monotherapy (P= 0.011). With respect to survival, no significant advantage was seen with combination therapy over monotherapy (P= 0.438). Infusion-related reactions were reported in 11.1% of our patients, while cardiotoxicity was reported in12.5%.

Conclusions. Overall, we found that trastuzumab performs better in the clinical setting than it did in the pivotal trials with respect to TTF (2.5 vs. 2.4 months and 8.2 vs. 6.9 months), but not as well with respect to survival (10.0 vs. 13.0 months and 21.0 vs. 25.1 months). In comparison to the product monograph, we report a significantly lower incidence of infusion-related reactions and a slightly higher incidence of cardiotoxicity.

Key Words: adverse drug reactions • Canada • clinical effectiveness • metastatic breast cancer • monoclonal • trastuzumab

Journal of Oncology Pharmacy Practice, Vol. 8, No. 1, 19-25 (2002)
DOI: 10.1191/1078155202jp089oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?